Search clinical trials for: stage II melanoma

Total 41486 results

The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)

Malignant Melanoma Stage III

Austria, Netherlands, Australia, Sweden
NYU Langone Health

Active, not recruiting

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma

United States
Bristol-Myers Squibb

Active, not recruiting

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K)

Melanoma

Italy, Poland, United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Netherlands, Norway, Romania, Spain, Switzerland, United Kingdom, Sweden
Case Comprehensive Cancer Center

Active, not recruiting

Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting

Stage III Melanoma | Stage IV Cutaneous Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

HIV Infection | Hepatocellular Carcinoma | Non-Hodgkin Lymphoma | Metastatic Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Kaposi Sarcoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable... and other conditions

United States
Massachusetts General Hospital
Conquer Cancer Foundation

Active, not recruiting

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer (UPLIFT)

Stage IV Non-Small Cell Lung Cancer | Stage IV Bladder Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Immunotherapy | Immune Checkpoint Inhibitors | Stage IV Gastric Cancer | Stage IV Merkel Cell Carcinoma | Stage IV Colorectal Cancer | Stage IV Esophageal Cancer | Advanced Lung Cancer | Stage IV Renal... and other conditions

United States
University of Colorado, Denver
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

Stage IV Melanoma | Advanced Melanoma | Stage III Melanoma

United States
Novartis Pharmaceuticals

Available

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

Melanoma | Adjuvant
National Cancer Institute (NCI)

Completed

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Canada
The Methodist Hospital Research Institute

Completed

Olive Oil for High Risk Breast Cancer Prevention in Women

Breast Cancer

United States
The Netherlands Cancer Institute
Amgen

Active, not recruiting

Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease (NIVEC)

Melanoma Stage IV | Melanoma Stage III

Netherlands
Universitair Ziekenhuis Brussel

Completed

TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma (TraMel-WT)

Stage IV Melanoma | Stage III Melanoma

Belgium
Mayo Clinic

Active, not recruiting

Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

Melanoma

United States, Italy, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Mexico, Norway, Romania, Spain, Sweden, Switzerland, United Kingdom
John Kirkwood
Bristol-Myers Squibb

Active, not recruiting

Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
Melanoma Institute Australia
Merck Sharp & Dohme LLC; Novartis

Active, not recruiting

Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma (Neo Trio)

Melanoma

Australia
Melanoma Institute Australia

Active, not recruiting

Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma (Neo Combi)

Melanoma

Australia
Merck Sharp & Dohme LLC
European Organisation for Research and Treatment of Cancer

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)

Melanoma
Amgen

Completed

Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma

Unresectable Stage IIIB-IV Malignant Melanoma

Japan
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Terminated

Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Metastatic Melanoma | Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage III Mucosal Melanoma of the Head and Neck | Stage IVA Mucosal Melanoma of the Head and Neck | Stage IVB Mucosal Melanoma of the Head and Neck | Stage IVC Mucosal Melanoma...

United States
Memorial Sloan Kettering Cancer Center
Schering-Plough

Completed

Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma

Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer

Malignant Solid Neoplasm | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Melanoma (Skin)

United States
CINJRegulatory
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Medical University of Graz
Bristol-Myers Squibb

Terminated

The IRMI-FMT Trial

Malignant Melanoma Stage III | Malignant Melanoma Stage IV | Fecal Microbiota Transplantation

Austria
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

Melanoma (Skin)

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Terminated

FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Melanoma | Malignant Melanoma
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI); NCIC Clinical Trials Group; Children's Oncology... and other collaborators

Active, not recruiting

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Melanoma (Skin)

United States, Canada, Australia, South Africa
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin

Melanoma (Skin)

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Locally Advanced Melanoma | Unresectable Melanoma | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
Amgen

Completed

Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma

Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma

United States, Poland, France, Russian Federation, Spain, Australia, Greece, Switzerland, Brazil
Dana-Farber Cancer Institute
Partner Therapeutics (PTx)

Withdrawn

Sargramostim (GM-CSF) + PD-1

Metastatic Melanoma | Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Genentech, Inc.

Completed

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Array BioPharma

Completed

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Melanoma

United States
F. Stephen Hodi, MD
MedImmune LLC

Completed

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Metastatic Melanoma

United States
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, France, Australia, Italy, Greece, Israel, Russian Federation, New Zealand, Austria, United Kingdom, Netherlands, Portugal, Poland, Czechia, Romania
QBiotics Group Limited

Terminated

A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma

Melanoma

Australia
QBiotics Group Limited
Merck Sharp & Dohme LLC

Terminated

A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

Melanoma

Australia
The Christie NHS Foundation Trust
University of Liverpool; University of Manchester; Manchester Academic Health...

Terminated

Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION (DETECTION)

Melanoma (Skin) | Melanoma, Stage II

United Kingdom
OncoSec Medical Incorporated
Merck Sharp & Dohme LLC

Active, not recruiting

Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment (Keynote-695)

Stage III/IV Melanoma

United States, Australia, Canada, Italy, Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
University of Utah
Natera, Inc.; Intermountain Medical Center

Active, not recruiting

Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)

Melanoma

United States
Gustave Roussy, Cancer Campus, Grand Paris

Completed

A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (NIVIPIT)

Stage III/IV Melanoma

France
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); University of Virginia

Completed

Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma

Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

Melanoma | Skin Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Iovance Biotherapeutics, Inc.; Prometheus Inc.

Completed

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

Skin Cancer | Melanoma (Skin)

United States
H. Lee Moffitt Cancer Center and Research Institute
Exelixis

Completed

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Melanoma (Skin)

United States

Search clinical trials for: stage II melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations